Teva Canada launches first Restasis generic
Teva Canada is bringing the Great White North its first Restasis generic. The Toronto-based Teva subsidiary’s generic is indicated to treat moderate-to-moderately severe ocular staining, reduction in tear production and such fluctuating visual symptoms as blurred vision.
“Dry eye disease negatively impacts a patient's quality of life and has the potential to cause long-term eye damage, so it's crucial patients have access to affordable treatment options made to the highest standards,” said Christine Poulin, senior vice president and general manager, Teva Canada. “With as many as 10 million Canadians potentially suffering from dry eye disease, Teva-Cyclosporine ophthalmic emulsion will provide relief for the patients' eyes as well as budget.”
The product had a Canadian market size of roughly $46.5 million for the 12 months ended in March, according to IQVIA data. The Restasis generic currently is available to pharmacies. It joins Teva Canada’s eight-product ophthalmic portfolio, the company said.
“Dry eye disease negatively impacts a patient's quality of life and has the potential to cause long-term eye damage, so it's crucial patients have access to affordable treatment options made to the highest standards,” said Christine Poulin, senior vice president and general manager, Teva Canada. “With as many as 10 million Canadians potentially suffering from dry eye disease, Teva-Cyclosporine ophthalmic emulsion will provide relief for the patients' eyes as well as budget.”
The product had a Canadian market size of roughly $46.5 million for the 12 months ended in March, according to IQVIA data. The Restasis generic currently is available to pharmacies. It joins Teva Canada’s eight-product ophthalmic portfolio, the company said.